Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 06 09 2022
accepted: 25 11 2022
entrez: 5 1 2023
pubmed: 6 1 2023
medline: 7 1 2023
Statut: epublish

Résumé

Factors associated with long-term sequelae emerging after the acute phase of COVID-19 (so called "long COVID") are unclear. Here, we aimed to identify risk factors for the development of COVID-19 sequelae in a prospective cohort of subjects hospitalized for SARS-CoV-2 infection and followed up one year after discharge. A total of 324 subjects underwent a comprehensive and multidisciplinary evaluation one year after hospital discharge for COVID-19. A subgroup of 247/324 who consented to donate a blood sample were tested for a panel of circulating cytokines. In 122 patients (37.8%) there was evidence of at least one persisting physical symptom. After correcting for comorbidities and COVID-19 severity, the risk of developing long COVID was lower in the 109 subjects admitted to the hospital in the third wave of the pandemic than in the 215 admitted during the first wave, (OR 0.69, 95%CI 0.51-0.93, p=0.01). Univariable analysis revealed female sex, diffusing capacity of the lungs for carbon monoxide (DLCO) value, body mass index, anxiety and depressive symptoms to be positively associated with COVID-19 sequelae at 1 year. Following logistic regression analysis, DLCO was the only independent predictor of residual symptoms (OR 0.98 CI 95% (0.96-0.99), p=0.01). In the subgroup of subjects with normal DLCO (> 80%), for whom residual lung damage was an unlikely explanation for long COVID, the presence of anxiety and depressive symptoms was significantly associated to persistent symptoms, together with increased levels of a set of pro-inflammatory cytokines: interferon-gamma, tumor necrosis factor-alpha, interleukin (IL)-2, IL-12, IL-1β, IL-17. In logistic regression analysis, depressive symptoms (p=0.02, OR 4.57 [1.21-17.21]) and IL-12 levels (p=0.03, OR 1.06 [1.00-1.11]) 1-year after hospital discharge were independently associated with persistence of symptoms. Long COVID appears mainly related to respiratory sequelae, prevalently observed during the first pandemic wave. Among patients with little or no residual lung damage, a cytokine pattern consistent with systemic inflammation is in place.

Identifiants

pubmed: 36601115
doi: 10.3389/fimmu.2022.1038227
pmc: PMC9807078
doi:

Substances chimiques

Interleukin-12 187348-17-0
Cytokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1038227

Investigateurs

Mattia Bellan (M)
Daria Apostolo (D)
Alice Albè (A)
Martina Crevola (M)
Errica Nicolò (E)
Giacomo Ratano (G)
Antonio Acquavivas (A)
Luigi Mario Castello (LM)
Stelvio Tonello (S)
Rosalba Minisini (R)
Davide D'Onghia (D)
Alessio Baricich (A)
Filippo Patrucco (F)
Patrizia Zeppegno (P)
Carla Gramaglia (C)
Gian Carlo Avanzi (GC)
Piero Emilio Balbo (PE)
Giulia Baldon (G)
Michela Barini (M)
Marco Battaglia (M)
Simone Bor (S)
Vincenzo Cantaluppi (V)
Giuseppe Cappellano (G)
Alessandro Carriero (A)
Sara Casella (S)
Annalisa Chiocchetti (A)
Daria Cuneo (D)
Eleonora Gambaro (E)
Mara Giordano (M)
Luisa Isabella (L)
Alberto Loro (A)
Debora Marangon (D)
Emanuele Mones (E)
Elena Paracchini (E)
Giuseppe Patti (G)
David James Pinato (DJ)
Chiara Puricelli (C)
Davide Raineri (D)
Roberta Rolla (R)
Pier Paolo Sainaghi (PP)
Stefano Tricca (S)
Mario Pirisi (M)

Informations de copyright

Copyright © 2022 Bellan, Apostolo, Albè, Crevola, Errica, Ratano, Tonello, Minisini, D’Onghia, Baricich, Patrucco, Zeppegno, Gramaglia, Balbo, Cappellano, Casella, Chiocchetti, Clivati, Giordano, Manfredi, Patti, Pinato, Puricelli, Raineri, Rolla, Sainaghi, Pirisi and the No-More COVID study group.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

An Bras Dermatol. 2021 Sep-Oct;96(5):551-557
pubmed: 34281739
Front Psychiatry. 2022 Jun 17;13:862651
pubmed: 35782424
Curr Med Chem. 2021;28(26):5328-5338
pubmed: 33297909
Respir Physiol Neurobiol. 2021 Jun;288:103644
pubmed: 33647535
Ann Med. 2022 Dec;54(1):1473-1487
pubmed: 35594336
Clin Microbiol Infect. 2022 Apr;28(4):611.e9-611.e16
pubmed: 34763058
J Clin Med. 2022 May 24;11(11):
pubmed: 35683340
Cell Rep Med. 2022 Jun 21;3(6):100663
pubmed: 35732153
Cells. 2021 Dec 02;10(12):
pubmed: 34943905
Eur J Intern Med. 2022 Mar;97:36-41
pubmed: 34903448
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
Clin Med (Lond). 2021 Jan;21(1):e68-e70
pubmed: 33144403
Nat Immunol. 2022 Feb;23(2):210-216
pubmed: 35027728
Sci Rep. 2021 Nov 22;11(1):22666
pubmed: 34811387
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Cells. 2021 Aug 19;10(8):
pubmed: 34440903
PLoS One. 2022 Jan 13;17(1):e0261142
pubmed: 35025917
J Am Geriatr Soc. 1968 May;16(5):622-6
pubmed: 5646906
Arch Med Res. 2021 Aug;52(6):575-581
pubmed: 33962805
JAMA Dermatol. 2017 Jun 1;153(6):600-602
pubmed: 28355451
Nat Immunol. 2022 Feb;23(2):194-202
pubmed: 35105985
Immunity. 2019 Apr 16;50(4):851-870
pubmed: 30995503
Int J Environ Res Public Health. 2021 Feb 05;18(4):
pubmed: 33562427
JAAD Int. 2022 Jun;7:67-77
pubmed: 35224518
Front Immunol. 2020 May 27;11:1206
pubmed: 32574269
Lancet Respir Med. 2022 Sep;10(9):863-876
pubmed: 35568052
JAMA Netw Open. 2021 Jan 4;4(1):e2036142
pubmed: 33502487
J Clin Med. 2021 Sep 14;10(18):
pubmed: 34575251
J Infect Dis. 2022 Jun 15;225(12):2155-2162
pubmed: 35079804
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32706339
Trends Mol Med. 2021 Sep;27(9):895-906
pubmed: 34175230
J Natl Cancer Inst. 2022 Jul 11;114(7):979-987
pubmed: 35417006
Science. 2022 Mar 11;375(6585):1122-1127
pubmed: 35271343
Sci Rep. 2020 Nov 26;10(1):20731
pubmed: 33244144
Front Cell Infect Microbiol. 2022 Jun 30;12:922422
pubmed: 35846757
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Cytokine. 2021 Jan;137:155323
pubmed: 33045526
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
J Clin Med. 2021 Sep 02;10(17):
pubmed: 34501430
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Open Forum Infect Dis. 2021 Jul 16;8(8):ofab384
pubmed: 34386546
Front Psychiatry. 2021 Jun 10;12:667385
pubmed: 34177656
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Front Immunol. 2020 May 29;11:1131
pubmed: 32574265

Auteurs

Mattia Bellan (M)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Daria Apostolo (D)

Università del Piemonte Orientale (UPO), Novara, Italy.

Alice Albè (A)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Martina Crevola (M)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Nicolò Errica (N)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Giacomo Ratano (G)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Stelvio Tonello (S)

Università del Piemonte Orientale (UPO), Novara, Italy.

Rosalba Minisini (R)

Università del Piemonte Orientale (UPO), Novara, Italy.

Davide D'Onghia (D)

Università del Piemonte Orientale (UPO), Novara, Italy.

Alessio Baricich (A)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Filippo Patrucco (F)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Patrizia Zeppegno (P)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Carla Gramaglia (C)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Piero Emilio Balbo (PE)

"AOU Maggiore della Carità", Novara, Italy.

Giuseppe Cappellano (G)

Università del Piemonte Orientale (UPO), Novara, Italy.

Sara Casella (S)

Università del Piemonte Orientale (UPO), Novara, Italy.

Annalisa Chiocchetti (A)

Università del Piemonte Orientale (UPO), Novara, Italy.

Elisa Clivati (E)

"AOU Maggiore della Carità", Novara, Italy.

Mara Giordano (M)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Marcello Manfredi (M)

Università del Piemonte Orientale (UPO), Novara, Italy.

Giuseppe Patti (G)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

David James Pinato (DJ)

Università del Piemonte Orientale (UPO), Novara, Italy.
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.

Chiara Puricelli (C)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Davide Raineri (D)

Università del Piemonte Orientale (UPO), Novara, Italy.

Roberta Rolla (R)

Università del Piemonte Orientale (UPO), Novara, Italy.

Pier Paolo Sainaghi (PP)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Mario Pirisi (M)

Università del Piemonte Orientale (UPO), Novara, Italy.
"AOU Maggiore della Carità", Novara, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH